跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 2026-10-03AI 评分57

地理性萎缩药企 Aviceda 因 II 期失败将关停

Geographic atrophy biotech Aviceda to shut down after Phase 2 fail

AI 导读

地理性萎缩药企 Aviceda Therapeutics 因 II 期临床试验失败将关停公司。正文提到该企业原计划今年将一款眼部药物推进至 III 期,但此前中期临床数据出现挫折,报道在正文处被订阅墙截断。

正文

Avice­da Ther­a­peu­tics, a biotech that had planned to take an eye drug in­to Phase 3 this year de­spite a mid-stage clin­i­cal set­back, is in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news